At RPRD, our team of experts lead in the implementation and advancement of precision medicine. Their decades of experience developing innovative solutions in medical genetics and their thoughtful consultancy guides clinicians, researchers, and drug developers as they implement and advance precision medicine in their fields.

Ulrich Broeckel, MD

Founder & Chief Executive Officer

Ulrich Broeckel, MD, is a leading physician-scientist with over 20 years of experience in genetics and genomics and more than 10 years of experience in clinical diagnostics. He is an expert in translational pharmacogenomics research and is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the NIH initiatives on clinical pharmacogenomics. Dr. Broeckel also serves as Professor of Pediatrics, and Section Chief of Genomic Pediatrics, at the Medical College of Wisconsin. Read more about Dr. Broeckel and his research team’s scientific achievements and research interest.

David Bick, MD

Medical Director

David Bick, MD, received his medical degree from George Washington University School of Medicine and completed his residency in Pediatrics and fellowship in Human Genetics at Yale-New Haven Hospital in New Haven, CT.  He is board-certified in Pediatrics, Clinical Genetics, and Clinical Molecular Genetics and has over 30 years of clinical and laboratory experience. Dr. Bick is a leader in the field of genomic medicine. His laboratories at the Medical College of Wisconsin, and Children’s Hospital of Wisconsin, were the first in the world to offer whole genome sequencing as a clinical test.

Amy Turner, MS

Director, Operations and Innovation

Amy is a leading scientist with over 15 years of experience in pharmacogenomics and precision medicine translational research. She is responsible for RPRD’s cutting-edge method development and lab operation. Amy is an active participant of the PharmVar Consortium and serves as a Gene Expert Panel member. She leads multiple collaborative projects with academic institutions, healthcare organizations, and drug developers to further all pharmacogenomics applications. Amy’s awareness of technological trends coupled with her extensive insight into the dynamic pharmacogenomics landscape allows her to provide RPRD clients with the most advanced pharmacogenomics consultation available. She received her Master of Science in Pharmacogenomics from Manchester University, Indiana.

Andrea Matter, MS

Director, Regulatory Affairs

Andrea leverages over 15 years of experience in clinical diagnostics, specializing in CLIA/CAP compliance, quality management, and GMP documentation. She provides consultation to RPRD clients on all of their compliance needs, ranging from patient privacy (HIPAA) and safety for healthcare management to understanding FDA guidelines. Andrea understands that robust quality standards and continuous improvement are the keys to providing RPRD clients with superior pharmacogenomics results. Testing accuracy and patient safety is always her top priority.

In Memoriam

Gunter Scharer MD, PhD †

Founding Chief Medical Officer & Medical Director

Gunter Scharer, MD PhD, passed away unexpectedly on January 12, 2024. He was a critical member when we founded RPRD and he served as the Founding Chief Medical Officer and Medical Director until his passing.

Dr. Scharer was a medical geneticist with 20+ years of clinical and laboratory experience. He was board certified in Clinical Genetics, Clinical Molecular Genetics, and Medical Biochemical Genetics, and licensed to practice in multiple states. As a renowned geneticist with deep clinical experience, he provided critical expertise and input for our clinical testing operations. He was a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Pharmacogenomics Research Network (PGRN). Prior to joining RPRD, Dr. Scharer was the director of the Department of Medical Genetics and Genomics at Children’s Minnesota and Adjunct Associate Professor in Pediatrics at the Medical College of Wisconsin.

He is deeply missed by everyone at RPRD and the broader clinical genetics community. His commitment and dedication were exemplary. We will continue our mission and work in his memory.